iBio, Inc.IBIONYSE
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank69
3Y CAGR+31.4%
5Y CAGR-5.6%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+31.4%/yr
Quarterly compound
5Y CAGR
-5.6%/yr
Recent acceleration
Percentile
P69
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 20.56% |
| Q3 2025 | 10.11% |
| Q2 2025 | 69.15% |
| Q1 2025 | 1.55% |
| Q4 2024 | 43.83% |
| Q3 2024 | 14.47% |
| Q2 2024 | 26.11% |
| Q1 2024 | -41.11% |
| Q4 2023 | -4.42% |
| Q3 2023 | -31.83% |
| Q2 2023 | -10.89% |
| Q1 2023 | -4.86% |
| Q4 2022 | 9.07% |
| Q3 2022 | -59.79% |
| Q2 2022 | 93.64% |
| Q1 2022 | 76.01% |
| Q4 2021 | 63.93% |
| Q3 2021 | -63.38% |
| Q2 2021 | 43.25% |
| Q1 2021 | -8.93% |
| Q4 2020 | 27.50% |
| Q3 2020 | 219.38% |
| Q2 2020 | -46.76% |
| Q1 2020 | 23.31% |
| Q4 2019 | -9.11% |
| Q3 2019 | -39.84% |
| Q2 2019 | 11.77% |
| Q1 2019 | 14.14% |
| Q4 2018 | 13.26% |
| Q3 2018 | 7.87% |
| Q2 2018 | 7.87% |
| Q1 2018 | -2.72% |
| Q4 2017 | 0.81% |
| Q3 2017 | -11.42% |
| Q2 2017 | -2.11% |
| Q1 2017 | 8.29% |
| Q4 2016 | 27.93% |
| Q3 2016 | -3.87% |
| Q2 2016 | -18.61% |
| Q1 2016 | 48.86% |